File(s) under permanent embargo
The science and practice of lithium therapy
journal contribution
posted on 2012-03-01, 00:00 authored by G Malhi, M Tanious, P Das, Michael BerkMichael BerkIntroduction: Despite more that 60 years of clinical experience, the effective use of lithium for the treatment of mood disorder, in particular bipolarity, is in danger of becoming obsolete. In part, this is because of exaggerated fears surrounding lithium toxicity, acute and long-term tolerability and the encumbrance of life-long plasma monitoring. Recent research has once again positioned lithium centre stage and amplified the importance of understanding its science and how this translates to clinical practice.
Objective: The aim of this paper is to provide a sound knowledge base as regards the science and practice of lithium therapy.
Method: A comprehensive literature search using electronic databases was conducted along with a detailed review of articles known to the authors pertaining to the use of lithium. Studies were limited to English publications and those dealing with the management of psychiatric disorders in humans. The literature was synthesized and organized according to relevance to clinical practice and understanding.
Results: Lithium has simple pharmacokinetics that require regular dosing and monitoring. Its mechanisms of action are complex and its effects are multi-faceted, extending beyond mood stability to neuroprotective and anti-suicidal properties. Its use in bipolar disorder is under-appreciated, particularly as it has the best evidence for prophylaxis, qualifying it perhaps as the only true mood stabilizer currently available. In practice, its risks and tolerability are exaggerated and can be readily minimized with knowledge of its clinical profile and judicious application.
Conclusion: Lithium is a safe and effective agent that should, whenever indicated, be used first-line for the treatment of bipolar disorder. A better understanding of its science alongside strategic management of its plasma levels will ensure both wider utility and improved outcomes.
Objective: The aim of this paper is to provide a sound knowledge base as regards the science and practice of lithium therapy.
Method: A comprehensive literature search using electronic databases was conducted along with a detailed review of articles known to the authors pertaining to the use of lithium. Studies were limited to English publications and those dealing with the management of psychiatric disorders in humans. The literature was synthesized and organized according to relevance to clinical practice and understanding.
Results: Lithium has simple pharmacokinetics that require regular dosing and monitoring. Its mechanisms of action are complex and its effects are multi-faceted, extending beyond mood stability to neuroprotective and anti-suicidal properties. Its use in bipolar disorder is under-appreciated, particularly as it has the best evidence for prophylaxis, qualifying it perhaps as the only true mood stabilizer currently available. In practice, its risks and tolerability are exaggerated and can be readily minimized with knowledge of its clinical profile and judicious application.
Conclusion: Lithium is a safe and effective agent that should, whenever indicated, be used first-line for the treatment of bipolar disorder. A better understanding of its science alongside strategic management of its plasma levels will ensure both wider utility and improved outcomes.
History
Journal
Australian and New Zealand journal of psychiatryVolume
46Issue
3Pagination
192 - 211Publisher
Sage PublicationsLocation
London, EnglandPublisher DOI
ISSN
0004-8674eISSN
1440-1614Language
engPublication classification
C1 Refereed article in a scholarly journalCopyright notice
2012, Sage publishersUsage metrics
Read the peer-reviewed publication
Categories
Keywords
bipolar disorderlithiummood stabilizerneuroprotectionsuicideScience & TechnologyLife Sciences & BiomedicinePsychiatryMAGNETIC-RESONANCE-SPECTROSCOPYANXIETY TREATMENTS CANMATSINUS NODE DYSFUNCTIONCLINICAL-PRACTICE RECOMMENDATIONSBIPOLAR DISORDER PATIENTSCHRONIC KIDNEY-DISEASEMOUSE CEREBRAL-CORTEXD-ASPARTATE RECEPTORCANADIAN NETWORKMOOD STABILIZERS